2022
DOI: 10.1007/s12282-022-01385-7
|View full text |Cite
|
Sign up to set email alerts
|

Comprehensive analysis of DRAIC and TP53TG1 in breast cancer luminal subtypes through the construction of lncRNAs regulatory model

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 37 publications
0
3
0
Order By: Relevance
“…LINC00493 and TP53TG1 are enriched and co-released in extracellular vesicles from colorectal cancer cells (45). Previous studies have highlighted the ambivalent oncogenic or tumor suppressor activity of TP53TG1 in luminal breast cancer (46, 47).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…LINC00493 and TP53TG1 are enriched and co-released in extracellular vesicles from colorectal cancer cells (45). Previous studies have highlighted the ambivalent oncogenic or tumor suppressor activity of TP53TG1 in luminal breast cancer (46, 47).…”
Section: Resultsmentioning
confidence: 99%
“…Previous studies have highlighted the ambivalent oncogenic or tumor suppressor activity of TP53TG1 in luminal breast cancer (46,47).…”
Section: Lncrnas Associated To the Topic 19 Are Specifically Expresse...mentioning
confidence: 99%
“…On the other hand, our investigation revealed TP53TG1 to be a safeguarding element. Previous investigations have demonstrated a significant association between TP53TG1 and lymph node infiltration in breast cancer patients, suggesting its potential oncogenic role in the official cavity subtype of breast cancer [39], possibly due to its characteristic expression in a specific subtype. Overall, our model based on these eight DALs holds promise for early detection and prognostic prediction in BRCA patients, highlighting the potential clinical significance of these lncRNAs in the management of breast cancer.…”
Section: Discussionmentioning
confidence: 97%
“…LINC00493 and TP53TG1 are enriched and co-released in extracellular vesicles from colorectal cancer cells [48]. Previous studies have highlighted the ambivalent oncogenic or tumor suppressor activity of TP53TG1 in luminal breast cancer [49,58].…”
Section: Discussionmentioning
confidence: 99%